X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.
Lead Product(s): RBI-4000
Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-4000
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Replicate Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
Murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and to generate high affinity antibodies that recognize different epitopes on the SARS-CoV-2 spike protein.
Lead Product(s): Murine Monoclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 12, 2022
Details:
IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.
Lead Product(s): Cannabidiol,Isoflurane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Incannex Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 02, 2022
Details:
Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.
Lead Product(s): Liafensine
Therapeutic Area: Psychiatry/Psychology Product Name: DB104
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Denovo Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
As part of the collaboration, Curia’s experienced process development team will support the GMP production of Replicate Bioscience’s srRNA vectors up to eight-liter scale (8L), which can be used in Phase 1 through pivotal clinical trials.
Lead Product(s): srRNA Therapeutic
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Replicate Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 09, 2022
Details:
Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cassiopea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 30, 2020
Details:
Bryostatin-1 is the company’s lead compound being developed to improve patient outcomes by amplifying the response and increasing the durability of targeted cancer immunotherapies.
Lead Product(s): Bryostatin-1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: BryoLogyx Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Curia has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at Curia’s drug product manufacturing facility in Albuquerque, New Mexico.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 03, 2020
Details:
Curia will provide research, development and cGMP manufacturing of a proprietary psilocybin active pharmaceutical ingredient to support the clinical development of TRP-8802, TRP-8803 and TRP-8804 programs.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: TRP-8802
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tryp Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 13, 2020
Details:
The companies together are undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.
Lead Product(s): Merimepodib,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: VX-497
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioSig Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
